Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 304 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HPV Infections Clear all

Conditions: HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma, Anal HSIL
Interventions: EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Warts, Human Papilloma Virus
Interventions: Candida albicans Skin Test Antigen; Biological
Lead sponsor: Nielsen BioSciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Fort Smith, Arkansas

Conditions: Head and Neck Cancer, Head and Neck Neoplasms
Interventions: M7824, N803, TriAd vaccine; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HPV Infection, Vaccine-Preventable Diseases
Interventions: HPV game; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 11 Years to 14 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: HPV, Oropharyngeal Squamous Cell Carcinoma
Interventions: Screening; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Warts
Interventions: Resiquimod; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Fridley, Minnesota

Conditions: Recurrent Respiratory Papillomatosis (RRP), Juvenile-onset Recurrent Respiratory Papillomatosis, Papillomavirus Infections
Interventions: Zopapogene imadenovec-drba; Biological
Lead sponsor: Precigen, Inc; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Verruca Vulgaris
Interventions: Liquid Nitrogen Cryotherapy, Pulsed 1064nm Nd:YAG; Procedure
Lead sponsor: Trinity Health Michigan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Ypsilanti, Michigan

Conditions: Infections, Papillomavirus
Interventions: HPV 16/18 L1 AS04, HPV-16/18/31/45 L1 AS04 Formulation 1, HPV-16/18/31/45 L1 AS04 Formulation 2, HPV-16/18/31/45 L1 AS04 Formulation 3, HPV-16/18/31/45 L1 AS04 Formulation 4, HPV-16/18/31/45 L1 AS04 Formulation 5, HPV-16/18/31/45 L1 AS04 Formulation 6; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 383 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 5
States / cities: Aurora, Colorado • Golden, Colorado • Kingston, Rhode Island + 1 more

Conditions: Cervical Cancer, Genital Warts
Interventions: Received HPV vaccine first, Received concomitant vaccines first; Biological
Lead sponsor: Duke University; Other
Eligibility: 9 Years to 18 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Genital Warts
Interventions: 2.5% imiquimod cream, 3.75% imiquimod cream, Placebo cream; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 43
States / cities: Jonesboro, Arkansas • Carmichael, California • Chico, California + 35 more

Conditions: HPV Infection, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: Salivary TTMV-HPV DNA Test, Blood TTMV-HPV DNA Test; Diagnostic Test
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention, Adherence, Patient
Interventions: Culturally Tailored Multimedia Psychoeducational HPV Intervention, General HPV Multimedia Psychoeducational Control Group; Behavioral
Lead sponsor: University of Texas, El Paso; Other
Eligibility: 18 Years to 45 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Infections, Papillomavirus
Interventions: Gynaecological follow-up; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2,022 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 18
States / cities: Clearwater, Florida • Miami, Florida • Honolulu, Hawaii + 14 more

Conditions: Hpv
Interventions: Communication, Standing Orders; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 9 Years to 17 Years
Enrollment: 16,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Decision Aid, Hpv
Interventions: Patient decision aid, Control; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 27 Years to 45 Years
Enrollment: 632 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV), Placebo/QHPV; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 7 Years to 12 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 32
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 24 more

Conditions: HSIL, High Grade Squamous Intraepithelial Lesions, Anal Cancer, HPV-Related Squamous Cell Carcinoma, Human Papilloma Virus, Human Papillomavirus Infection, Ain III
Interventions: BARRX™ Anorectal Wand; Device
Lead sponsor: Stephen E. Goldstone; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Cervical Cancer, Papillomavirus Infection, Uterine Diseases, Uterine Cervical Disease
Interventions: COPAN 552c.80 FLOQSwab; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 3,367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Verruca (Warts)
Interventions: Occlusive Heat Patch; Device
Lead sponsor: Yale University; Other
Eligibility: 5 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HPV Infection, HPV Vaccine
Interventions: HPV vaccine; Biological
Lead sponsor: University of Washington; Other
Eligibility: 27 Years to 45 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Interventions: VP-102; Combination Product
Lead sponsor: Verrica Pharmaceuticals Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Bowling Green, Kentucky • Owensboro, Kentucky • New York, New York + 1 more

Conditions: Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology, Cervical Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Oral Cavity Infection
Interventions: Human papillomavirus 9-valent vaccine, recombinant, human papillomavirus vaccine, recombinant; Biological
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Papillomavirus Infections, Coronavirus Disease (COVID-19)
Interventions: 9vHPV Vaccine, mRNA-1273 Vaccine; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 9 Years to 11 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 38
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more

Search by objective public record fields.

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

Candin Safety & Efficacy Study for the Treatment of Warts

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Game-Based Intervention to Promote HPV Vaccination

Post-treatment Surveillance in HPV+ Oropharyngeal SCC

Study With a Topical Gel to Treat Common Warts in Adults

Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children

Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

Alternate Dosing Schedules Study for HPV Vaccine

Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts

The SPOT-HPV Study

Culturally Tailored HPV Psychoeducational Multimedia Intervention

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination

Patient Decision Aid Tool for HPV Vaccination Among Adults Ages 27-45 Years Old

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand

HPV Self-Sampling in Somali Women (Isbaar Project)

A Comparative Study of Occlusive Heat Patch in the Treatment of Warts

Immunogenicity of Fractional Dose of the HPV Vaccines

Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)